Participants with transthyretin amyloid cardiomyopathy (ATTR CM)
Conditions
Brief summary
Number of treatment emergent adverse events from baseline (week 0) up to visit 39 (week 156)
Detailed description
Change in 6-minute walk test (6MWT) from baseline (week 0) to visit 28 (week 104), Change in NT-proBNP from baseline (week 0) to visit 28 (week 104), Change in myocardial extracellular volume from baseline (week 0) to visit 28 (week 104), Change in KCCQ-(CSS)2 from baseline (week 0) to visit 28 (week 104), Change in troponin I from baseline (week 0) to visit 28 (week 104), Change in GLS on echocardiography from baseline (week 0) to visit 28 (week 104)
Interventions
Sponsors
Novo Nordisk A/S
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Number of treatment emergent adverse events from baseline (week 0) up to visit 39 (week 156) | — |
Secondary
| Measure | Time frame |
|---|---|
| Change in 6-minute walk test (6MWT) from baseline (week 0) to visit 28 (week 104), Change in NT-proBNP from baseline (week 0) to visit 28 (week 104), Change in myocardial extracellular volume from baseline (week 0) to visit 28 (week 104), Change in KCCQ-(CSS)2 from baseline (week 0) to visit 28 (week 104), Change in troponin I from baseline (week 0) to visit 28 (week 104), Change in GLS on echocardiography from baseline (week 0) to visit 28 (week 104) | — |
Countries
Czechia, France, Germany, Italy, Netherlands, Portugal, Spain
Outcome results
None listed